Related Experiment Videos
Mature insulin production by engineered non-beta cells
Kuntang Shen1, Xinyu Qin, Huasheng Xiao
1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Chinese Medical Journal
|July 23, 2002
Summary
Researchers engineered human cells to secrete insulin, a potential breakthrough for type 1 diabetes treatment. This somatic gene therapy approach offers new possibilities for diabetes mellitus management.
Area of Science:
- Biotechnology
- Molecular Biology
- Endocrinology
Background:
- Type 1 diabetes requires insulin replacement therapy.
- Current therapies like islet transplantation have limitations.
- Engineering non-beta cells to produce insulin is a novel therapeutic strategy.
Purpose of the Study:
- To develop engineered human non-beta cells capable of secreting mature insulin.
- To explore the potential of these cells for type 1 diabetes replacement therapy.
Main Methods:
- Human proinsulin cDNA was mutated using overlap extension PCR to include furin cleavage sites.
- An expression vector with modified proinsulin cDNA was created.
- Hela, 293, and L02 cells were transfected, selected, and screened for insulin expression via radioimmunoassay and immunofluorescence staining.
Main Results:
- Mutated human proinsulin cDNA was successfully expressed in Hela, 293, and L02 cells at varying levels.
- Insulin expression ranged from 2.56 to 242.14 microIU/24 h/2.0 x 10(6) cells across different cell types and clones.
- Immunofluorescence confirmed proinsulin storage in the cytoplasm of L02 cells.
Conclusions:
- A functional, mutated human proinsulin cDNA was successfully generated and expressed in non-beta cells.
- This study supports the feasibility of somatic gene therapy for diabetes mellitus.
- Engineered non-beta cells show promise for future insulin replacement therapies.